Navigation Links
Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
Date:12/10/2013

AUSTIN, Texas, Dec. 10, 2013 /PRNewswire/ -- Savara Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic product, AeroVanc, as a Qualified Infectious Disease Product (QIDP) for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. The company also received Fast Track designation for AeroVanc pursuant to section 506(a)(1) of the Food and Drug Administration Safety and Innovation Act (FDASIA).

The QIDP and Fast Track designation provide AeroVanc access to certain incentives, including priority review associated with a New Drug Application (NDA) submission and an additional five years of exclusivity under the Hatch-Waxman Act upon FDA approval of AeroVanc. Last year AeroVanc received orphan designation, which provides the product seven years of market exclusivity, and various other incentives. 

"The recent QIDP status forms an important part of our market exclusivity strategy," says Rob Neville, CEO of Savara Pharmaceuticals. "This designation along with Orphan Drug status, our formulation patent protection and our inhalation device exclusivity creates a very robust protection from competition."

Savara Pharmaceuticals is currently conducting a nationwide Phase II clinical trial evaluating the safety and efficacy of AeroVanc in CF patients. For more information, please visit http://www.aerovanc.com.  

About AeroVanc
Vancomycin is an FDA-approved intravenously administered antibiotic with proven efficacy in the treatment of MRSA infections. AeroVanc is an investigational, proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. AeroVanc is currently being developed as a treatment for persistent MRSA lung infection in CF patients. By delivering vancomycin directly to the lungs, higher vancomycin concentrations are achieved at the site of infection, which is expected to lead to improved clinical efficacy. In addition, direct delivery of the drug into the lungs reduces exposure to the drug elsewhere in the body, and is thereby expected to reduce the risk of systemic drug-related side effects.

About Savara Pharmaceuticals
Savara Pharmaceuticals is a specialty pharmaceutical company developing AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. For more information, please see Savara's website at www.savarapharma.com, or www.aerovanc.com, or find us on Twitter, Facebook and LinkedIn.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals Appoints Two New Members to Its Board of Directors
2. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
3. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
4. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
5. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
8. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND
9. Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
10. Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
11. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)... , May 4, 2017 Clarius Mobile ... wireless, handheld ultrasound scanners this week at the ... Meeting (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians ... heart rate, and evaluate pregnancy-related complications like ectopic ...
Breaking Medicine Technology:
(Date:5/27/2017)... , ... May 27, 2017 , ... Hate visiting the dentist? You should go twice ... to take care of your teeth at home. Here are some dental tips to help ... Keep a small toothbrush in your work desk or a locker at school for a ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying ... emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease Association ...
(Date:5/26/2017)... ... , ... A new analysis of community health data reveals that four out ... Midwest. With the average cost of healthcare rising and the U.S. senior population expected ... and affordability of where they live. An annual 2017 report looked at a variety ...
(Date:5/26/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... Peace Agreements being discussed by President Donald Trump and the rest of the world. ... speed up peace talks in the continuous battle between Israel and Palestine. The world’s ...
(Date:5/26/2017)... ... ... the Cross”: the personal journey of Bob Massey and his faith in the Lord. ... Margaret Massey. Bob Massey is small in stature but big in character. As ... for others is apparent in all of his life decisions. , “I’m in the ...
Breaking Medicine News(10 mins):